A
ACTU
Actuate Therapeutics, Inc. Common stock
$0.43
Current Price
1W
1M
3M
6M
1Y
All
AI analysis
Read what the AI thinks of Actuate Therapeutics, Inc. Common stock in the app.
Analyses are generated by AI from public data and are not investment advice.
Get the app
Key figures
Dividend per share
—
Yield
—
EPS
-$0.89
P/E
—
Data as of Oct 8
Why it matters for the long term
Over 10-20 years, what drives a share up is the growth of its profits (EPS) + reinvested dividends. The P/E tells you whether you are paying a lot or a little for that growth. In short: rising EPS + reasonable P/E + growing dividend = good long-term candidate.
Upcoming events
Quarterly earnings
Expected EPS: -$0.17
Nov 13
Posts
No posts about ACTU yet.
About Actuate Therapeutics, Inc. Common stock
Actuate Therapeutics is a small clinical-stage biotech company. It develops experimental drugs, led by elraglusib, which it is testing mainly in hard-to-treat cancers such as pancreatic cancer. It has no approved products and no sales, so it pays its bills with money raised from investors until a drug is approved or a partner pays for it.